Need professional-grade analysis? Visit stockanalysis.com
$270.96M
N/A
N/A
N/A
Price Chart
Risk-Adjusted Performance
Protara Therapeutics Inc (TARA) Price Performance
Protara Therapeutics Inc (TARA) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $5.01, down 3.84% from the previous close.
Over the past year, TARA has traded between a low of $2.78 and a high of $7.56. The stock has gained 10.6% over this period. It is currently 33.7% below its 52-week high.
Protara Therapeutics Inc has a market capitalization of $270.96M.
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Company Info
- Sector
- Healthcare
- Industry
- Biological Products
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- N/A
- EBITDA
- $-64,187,000
- Profit Margin
- N/A
- EPS (TTM)
- -1.30
- Book Value
- 3.67
Technical Indicators
- 52 Week High
- $7.82
- 52 Week Low
- $2.77
- 50 Day MA
- $6.06
- 200 Day MA
- $4.66
- Beta
- 1.44
Valuation
- Trailing P/E
- N/A
- Forward P/E
- -3.60
- Price/Sales
- N/A
- Price/Book
- 1.37
- Enterprise Value
- $118.77M